{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:34:48Z","timestamp":1760888088226},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.lungcan.2007.05.018","type":"journal-article","created":{"date-parts":[[2007,7,7]],"date-time":"2007-07-07T07:14:20Z","timestamp":1183792460000},"page":"414-417","source":"Crossref","is-referenced-by-count":28,"title":["Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer"],"prefix":"10.1016","volume":"58","author":[{"given":"John Wen-Cheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Liang","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiu-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Juan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Chung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2007.05.018_bib1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"Pinkas-Kramarski","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.lungcan.2007.05.018_bib2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2007.05.018_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Raffaella","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2007.05.018_bib4","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.05.018_bib5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2007.05.018_bib6","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1016\/S0169-5002(03)92578-5","article-title":"Finals results of a Phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy (abstract P-611)","volume":"41","author":"Perez-Soler","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2007.05.018_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer.","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"issue":"9496","key":"10.1016\/j.lungcan.2007.05.018_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.lungcan.2007.05.018_bib9","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2005.08.409","article-title":"Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.lungcan.2007.05.018_bib10","doi-asserted-by":"crossref","first-page":"7778","DOI":"10.1200\/JCO.2005.02.4471","article-title":"Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma","volume":"23","author":"Garfield","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lungcan.2007.05.018_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.clon.2006.07.002","article-title":"Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash","volume":"18","author":"Walther","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.lungcan.2007.05.018_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.lungcan.2005.07.004","article-title":"Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer","volume":"50","author":"Viswanathan","year":"2005","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2007.05.018_bib13","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.lungcan.2007.05.018_bib14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"Brief report: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lungcan.2007.05.018_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jjco\/hyl057","article-title":"Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes","volume":"36","author":"Chou","year":"2006","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2007.05.018_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2006.06.005","article-title":"Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer","volume":"53","author":"Hsieh","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2007.05.018_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1101\/sqb.2005.70.056","article-title":"Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors","volume":"70","author":"Thomas","year":"2005","journal-title":"Cold Spring Harbor Symp Quant Biol"},{"issue":"1","key":"10.1016\/j.lungcan.2007.05.018_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ncponc0400","article-title":"Gefitinib response of erlotinib-refractory lung cancer involving meninges\u2014role of EGFR mutation","volume":"3","author":"Choong","year":"2006","journal-title":"Nat Clin Practice Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500207003133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500207003133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T05:39:58Z","timestamp":1556602798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500207003133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0169500207003133"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2007.05.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}